Search clinical trials for: Semaglutide G

Total 2421 results

Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Early Alzheimer's Disease

Canada, United States, Spain, Netherlands, United Kingdom, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, Poland, Denmark, Czechia, Ireland, Norway, Japan, Romania, South Africa, Sweden, Mexico, F... and more
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Type 2 Diabetes | Healthy Volunteers | High Blood Cholesterol Levels

Germany, Canada
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (STEP 2)

Obesity | Overweight

United States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 7)

Obesity | Diabetes Mellitus, Type 2 | Overweight

Korea, Republic of, Hong Kong, Brazil, China
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3)

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Type 2 Diabetes | Healthy Volunteers

United States, Canada
Sansum Diabetes Research Institute
Novo Nordisk A/S

Terminated

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Diabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)

United States
Novo Nordisk A/S

Recruiting

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) (OASIS 3)

Obesity | Overweight

China
Novo Nordisk A/S

Completed

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 5)

Obesity | Overweight

United States, Italy, Spain, Canada, Hungary
Novo Nordisk A/S

Completed

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 6)

Obesity | Overweight

Japan, Korea, Republic of
Novo Nordisk A/S

Completed

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)

Overweight or Obesity | Metabolism and Nutrition Disorder

United States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Obesity

Germany
Woman's
Novo Nordisk A/S

Recruiting

Treatment to Regress to Normoglycemia in Women With a Recent History of GDM (SWEET)

Pre Diabetes | Postpartum Disorder

United States
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (OASIS 2)

Overweight and Obesity

Japan, Korea, Republic of
Novo Nordisk A/S

Completed

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Obesity & Overweight

Denmark, Canada
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Obesity

Korea, Republic of, Thailand
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

Obesity

Spain, United States, France, Russian Federation, Canada, Colombia, South Africa, Norway, Denmark, Saudi Arabia, Sweden
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Obesity | Overweight | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Poland, Slovakia, Czechia
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Novo Nordisk A/S

Completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan, Hungary, Poland, Russian Federation, Bulgaria, Serbia, Greece, Denmark
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Healthy Volunteers Type 2 Diabetes

Japan
Novo Nordisk A/S

Completed

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Fundación Instituto de Estudios de Ciencias de...

Not yet recruiting

Effect Of Semaglutide In Coronary Atheroma Plaque (SEPLA)

Atheroscleroses, Coronary
Novo Nordisk A/S

Completed

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Healthy | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Healthy | Diabetes

Germany
Novo Nordisk A/S

Active, not recruiting

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Spain
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Hungary, Czechia
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Obesity

United States
University of Texas Southwestern Medical Center
University of North Carolina, Chapel Hill

Recruiting

DIALYSIS-TIR Study

Type 2 Diabetes | End Stage Renal Disease on Dialysis

United States
University Health Network, Toronto

Recruiting

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Major Depressive Disorder

Canada
Novo Nordisk A/S

Completed

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2

Sweden
Novo Nordisk A/S

Completed

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Hungary, Greece
Novo Nordisk A/S

Withdrawn

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (PIONEER REAL)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis | Hepatobiliary Disorders

United States, Russian Federation, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Spain, France, Bulgaria, Canada, Australia, Greece, Japan, Finland, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
Novo Nordisk A/S

Completed

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Japan

3

Subscribe